Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Cagrilintide B and Cagrilintide D in Overweight or Obesity
NCT07597018Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cagrilintide in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the total cagrilintide concentration-time curve at steady state and Maximum concentration of total cagrilintide at steady state. Started May 2026; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07597018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597018.